Advanced nanomedicine approach of JAK inhibitors: supporting treatment of rheumatoid arthritis

References

• 1. Ebel AV, O'Dell JR. Clinical features, diagnosis, and treatment of rheumatoid arthritis. Physician Assist. Clin. 6(1), 41–60 (2021).
  Google Scholar
• 2. Rani R, Raina N, Sharma A, Kumar P, Tulli HS, Gupta M. Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications. Naunyn Schmiedebergs Arch. Pharmacol. 396, 2287–2310 (2023).
  Medline CASGoogle Scholar
• 3. Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol. Med. 43(4), 148–155 (2020).
  MedlineGoogle Scholar
• 4. Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J. Inflamm. Res. 13, 519–531 (2020).
  Medline CASGoogle Scholar
• 5. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16(12), 843–862 (2017).
  Medline CASGoogle Scholar
• 6. Heidari B. Rheumatoid arthritis: early diagnosis and treatment outcomes. Caspian J. Int. Med. 2(1), 161 (2011).
  MedlineGoogle Scholar
• 7. Shen Q, Shu H, Xu X, Shu G, Du Y, Ying X. Tofacitinib citrate-based liposomes for effective treatment of rheumatoid arthritis. Die Pharmazie-Int. J. Pharm. Sci. 75(4), 131–135 (2020).
  CASGoogle Scholar
• 8. Wang L, Che K, Liu Y. Pharmacokinetics, distribution and efficacy of triptolide PLGA microspheres after intra-articular injection in a rat rheumatoid arthritis model. Xenobiotica 51(6), 703–715 (2021).
  Medline CASGoogle Scholar
• 9. Aldawsari MF, Alhowail AH, Anwer MK, Ahmed MM. Development of Diphenyl carbonate-crosslinked cyclodextrin based nanosponges for oral delivery of baricitinib: formulation, characterization and pharmacokinetic studies. Int. J. Nanomed. 18, 2239–2251 (2023).
  Medline CASGoogle Scholar
• 10. Radu A-F, Bungau SG. Nanomedical approaches in the realm of rheumatoid arthritis. Ageing Res. Rev. 87, 101927 (2023).
  Medline CASGoogle Scholar
• 11. Bashir S, Aamir M, Sarfaraz RM et al. Fabrication, characterization and in vitro release kinetics of tofacitinib-encapsulated polymeric nanoparticles: a promising implication in the treatment of rheumatoid arthritis. Int. J. Polym. Mater. Polym. Biomater. 70(7), 449–458 (2021).
  CASGoogle Scholar
• 12. Shen Q, Hu Q, Tang T et al. ICAM-1 targeted thermal-sensitive micelles loaded with tofacitinib for enhanced treatment of rheumatoid arthritis via microwave assistance. Biomater. Adv. 138, 212940 (2022).
  Medline CASGoogle Scholar
• 13. Gorantla S, Puppala ER, Naidu V, Saha RN, Singhvi G. Hyaluronic acid-coated proglycosomes for topical delivery of tofacitinib in rheumatoid arthritis condition: formulation design, in vitro, ex vivo characterization, and in vivo efficacy studies. Int. J. Biol. Macromol. 224, 207–222 (2023).
  Medline CASGoogle Scholar
• 14. Gorantla S, Puppala ER, Naidu V, Saha RN, Singhvi G. Design of chondroitin sulphate coated proglycosomes for localized delivery of tofacitinib for the treatment of rheumatoid arthritis. Eur. J. Pharm. Biopharm. 186, 43–54 (2023).
  Medline CASGoogle Scholar
• 15. Wang Z, Zhan C, Zeng F, Wu S. A biopolymer-based and inflammation-responsive nanodrug for rheumatoid arthritis treatment via inhibiting JAK-STAT and JNK signalling pathways. Nanoscale 12(45), 23013–23027 (2020).
  Medline CASGoogle Scholar
• 16. Ansari MJ, Alshahrani SM. Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer. Saudi Pharm. J. 27(4), 491–501 (2019).
  MedlineGoogle Scholar
• 17. Li Y, Li B, Wang G et al. Engineered protein and Jakinib nanoplatform with extraordinary rheumatoid arthritis treatment. Nano Res. 16, 1–9 (2023).
  CASGoogle Scholar